What is AMLo Biosciences?
AMLo Biosciences is a pioneering biotechnology firm dedicated to advancing cancer care through the development of prognostic and companion diagnostic tests. Their focus on melanoma and other oncological conditions aims to enhance patient outcomes by providing accurate predictions of disease progression. This allows for more optimized treatment strategies and efficient healthcare resource allocation. The company's foundation is built upon the expertise of its oncology-focused founding team, driving innovation in biomarker research to transform the landscape of cancer diagnostics.
How much funding has AMLo Biosciences raised?
AMLo Biosciences has raised a total of $2M across 1 funding round:
Unspecified
$2M
Unspecified (2020): $2M with participation from North East Innovation Fund, Northern Accelerator Seed Investment Fund, British Innovation Fund, Northstar Ventures, and Esperante Ventures
Key Investors in AMLo Biosciences
Northstar Ventures
Northstar Ventures is a venture capital firm focused on building high-growth businesses in North East England. They manage funds like the Finance for Business North East Accelerator Fund, investing in innovative, early-stage companies with capital ranging from £100k to £500k.
Esperante Ventures
Esperante Ventures is a private life sciences investment group that focuses on therapeutics and in vitro diagnostics companies in Europe, North America, and Israel. They typically invest between £200,000 and £1m, often in syndication with other venture capital entities.
North East Innovation Fund
Undisclosed investor participating in the funding round.
What's next for AMLo Biosciences?
With this substantial strategic investment, AMLo Biosciences is poised for significant expansion and global market penetration. The company's focus on improving patient outcomes through advanced diagnostic tools, particularly for malignant melanoma, positions it for substantial growth. Future developments will likely involve scaling production, expanding clinical validation, and launching their technology internationally to impact a larger patient population. This financing will be critical in accelerating their mission to revolutionize cancer care.
See full AMLo Biosciences company page
